This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.
ALK gene rearrangements are found in around 5 percent of lung cancer tumors and are more common in people with lung cancer who never smoked. Crizotinib is an oral drug that was found to inhibit the effects of the ALK gene and to stop or reverse tumor growth.
In this phase II trial, researchers followed 901 patients for safety and 261 patients for tumor response; all of the patients had at least one prior chemotherapy treatment for their lung cancer. The overall response rate to crizotinib treatment was 60 percent and the median progression free survival (PFS) was eight months, confirming prior findings that crizotinib shrinks ALK-positive lung cancers and demonstrates a high PFS rate.
¡°This trial demonstrates that we have a good opportunity to shrink cancers and improve symptoms for patients with this subtype of lung cancer,¡± said Gregory Riely, MD, PhD, lead author of the study and a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York who specializes in treating lung cancer. ¡°This confirms the results of prior studies and further shows that crizotinib can reduce the effects of symptoms, thereby improving the quality of life for thousands of patients who are diagnosed with this late-stage lung cancer. This study confirms that crizotinib is the standard of care for patients with ALK positive lung cancer.¡±
The abstract, ¡°Results of a Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC),¡± will be presented during the Plenary Session at 12:30 p.m., Central time on September 7, 2012. To speak with Gregory Riely, MD, PhD, please contact Michelle Kirkwood or Nicole Napoli on September 6-8, 2012, in the press office at the Chicago Marriott Downtown Magnificent Mile at 312-595-3188.Abstract 4
G. J. Riely1, T. L. Evans2, R. Salgia3, S. I. Ou4, S. N. Gettinger5, G. A. Otterson6, S. Lanzalone7, A. Polli8, A. T. Shaw9, 1Memorial Sloan-Kettering Cancer Center, New York, 2University of Pennsylvania, Philadelphia, 3University of Chicago, Chicago, 4University of California at Irvine, Irvine, Calif., 5Yale University School of Medicine, New Haven, Conn., 6The Ohio State University, Columbus, Ohio, 7Pfizer Italy Srl, Milan, Italy, 8Pfizer Inc., Milan, Italy, 9Massachusetts General Hospital Cancer Center, Boston
Purpose/Objective(s): Approximately 3-5% of NSCLC harbors ALK gene rearrangements. Crizotinib is a first-in-class, oral, small-molecule competitive ALK inhibitor with anti-MET activity.
Materials/Methods: PROFILE 1005 is an ongoing global, multicenter, open-label, single-arm, phase II study evaluating the safety and efficacy of crizotinib (250 mg BID in 3-week cycles) in patients with advanced ALK-positive NSCLC who progressed after ¡Ý1 chemotherapy for recurrent/advanced/metastatic disease. Tumor response was evaluated by RECIST 1.1 every 6 weeks.
Results: As of June 2011, 439 patients were evaluable for safety and 255 patients for tumor response. Median age was 53 years. The majority of patients were female (53%), never smokers (65%), and had adenocarcinoma (92%), ECOG PS 0-1 (83%) and ¡Ý2 prior chemotherapy regimens (85%). Among patients evaluable for efficacy, median treatment duration was 25 weeks (77% of patients still ongoing). ORR was 53% (95% CI: 47-60), disease control rate at 12 weeks was 85% (95% CI: 80-89), median duration of response was 43 weeks (96% CI 36-50) and median PFS was 8.5 months (95% CI: 6.2-9.9). The most frequent treatment-related AEs were visual effects (50%), nausea (46%), vomiting (39%), and diarrhea (35%), mostly grade 1-2. 29 patients (6.6%) had treatment-related SAEs, including dyspnea and pneumonitis (4 patients each; 0.9%), and febrile neutropenia and renal cyst (2 patients each; 0.5%).
Conclusions: Crizotinib demonstrated a high response rate and PFS, and a favorable tolerability profile. These results provide strong evidence for crizotinib as a standard of care for advanced ALK-positive NSCLC.
Author Disclosure Block: G.J. Riely: E. Research Grant; BMS, Pfizer, Merck, GSK, Infinity. G. Consultant; Chugai, Tragara, Ariad, Daiichi, Abbott. T.L. Evans: None. R. Salgia: None. S.I. Ou: E. Research Grant; Pfizer. F. Honoraria; Pfizer. G. Consultant; Pfizer. S.N. Gettinger: E. Research Grant; Pfizer. G.A. Otterson: E. Research Grant; Pfizer, Genentech, Tragara, Amgen, Pharmacyclics. G. Consultant; Genentech, Abraxis. S. Lanzalone: A. Employee; Pfizer. K. Stock; Pfizer. A. Polli: A. Employee; Pfizer. K. Stock; Pfizer. A.T. Shaw: E. Research Grant; Novartis, Astra Zeneca, Pfizer, Ariad. F. Honoraria; Novartis, Millenium. G. Consultant; Pfizer, Ariad, Chugai, Daiichi-Sankyo.Media Contacts
Michelle Kirkwood | EurekAlert!
Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences
What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy